Partnership will capture behavioural and physiological signals and predictive biomarkers in Beckley Psytech’s upcoming Phase 2 clinical trials. New digital strategy aims to improve patient outcomes and safety by integrating advanced digital tools into the psychedelic treatment journey.

Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s) Broad collaboration with Lophora will further strengthen Beckley Psytech’s world class management and R&D team

Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the 8th Annual LSX World Congress 2022.

Study represents continued efforts to further understand the clinical and pharmacological potential of 5-MeO-DMT. BPL-003 is Beckley Psytech’s innovative dry powder intranasal formulation of 5-MeO-DMT using FDA approved intranasal delivery devices. Data from Phase 1 will be used to select lead compound for upcoming Phase 2 in treatment resistant depression (TRD).

Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding Mellen, Chief Executive Officer, will attend the 32nd Annual Oppenheimer Healthcare Conference

Literature review highlights need for further clinical exploration of 5-MeO-DMT

Training programme to be conducted in partnership with industry-leading educational company, Fluence. Initiation of training represents key step to incorporate psychedelic-assisted psychotherapy to deliver potentially clinically meaningful improvements.

B Corporations represent a new kind of business philosophy to protect and develop the future of all stakeholders.

CEO to participate in a panel discussion on the topic of “Psychedelics: More Than Just a Trip” – January 5, 2022 at 10:00 am ET / 3:00 pm GMT

Cosmo Feilding Mellen will present at the H.C. Wainwright 2nd Annual Psychedelics Conference, taking place virtually on December 6th, 2021, and the Stifel 2nd annual conference The Future of Healthcare, taking place virtually on December 8th, 2021.